Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Activation-dependent epitopes in the terminal complement pathway.

T E Mollnes1, T Lea, J Tschopp

  • 1Institute of Immunology and Rheumatology, Rikshospitalet, University of Oslo, Norway.

Complement and Inflammation
|January 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Loco-regional complications of pharyngitis: the example of Lemierre's syndrome].

Revue medicale suisse·2015
Same author

Metabolic gene expression changes in astrocytes in Multiple Sclerosis cerebral cortex are indicative of immune-mediated signaling.

Brain, behavior, and immunity·2015
Same author

Proteoglycans in secretory granules of NK cells.

Immunology today·2014
Same author

A novel potent Fas agonist for selective depletion of tumor cells in hematopoietic transplants.

Blood cancer journal·2012
Same author

ER stress activates the NLRP3 inflammasome via an UPR-independent pathway.

Cell death & disease·2012
Same author

The death domain-containing protein Unc5CL is a novel MyD88-independent activator of the pro-inflammatory IRAK signaling cascade.

Cell death and differentiation·2011
Same journal

Computer-assisted kinetic assay for quantification of total complement activity.

Complement and inflammation·1991
Same journal

HLA complement markers in Italian narcoleptic patients with special emphasis on BfF subtyping.

Complement and inflammation·1991
Same journal

Sarcoidosis and major histocompatibility complex genes with special emphasis on BF F subtypes.

Complement and inflammation·1991
Same journal

Clinical manifestations in humans of combined C7 and C4 deficiency associated with low levels of C2, C8, and C9.

Complement and inflammation·1991
Same journal

Biomedical polymers differ in their capacity to activate complement.

Complement and inflammation·1991
Same journal

Bibliography of complement research for 1989.

Complement and inflammation·1991
See all related articles

The terminal complement complex (TCC) formation during complement activation causes significant changes in antigenicity, exposing new epitopes and hiding others. Assays using monoclonal antibodies can detect and quantify these changes for clinical applications.

Area of Science:

  • Immunology
  • Complement System Biology

Background:

  • Complement activation leads to the assembly of the terminal complement complex (TCC).
  • This assembly involves complement components C5, C6, C7, C8, and C9.
  • Significant antigenic alterations occur on these components during TCC formation.

Purpose of the Study:

  • To review the antigenic changes associated with TCC assembly.
  • To discuss the use of monoclonal antibodies in detecting and quantifying TCC.
  • To explore the clinical applications of TCC detection assays and propose standardized terminology for the terminal complement pathway.

Main Methods:

  • Review of existing literature on TCC assembly and antigenic changes.
  • Analysis of monoclonal antibodies targeting TCC neoepitopes and native epitopes.

Related Experiment Videos

  • Discussion of immunoassay methodologies for TCC detection and quantification.

    • Main Results:

    • TCC formation exposes numerous neoepitopes specific to the assembled complex.
    • Native-restricted epitopes on nonactivated complement components become concealed within the TCC.
    • Monoclonal antibodies are valuable tools for identifying and measuring TCC.

    Conclusions:

    • Antigenic modifications during TCC assembly are critical for its detection.
    • Monoclonal antibody-based assays offer robust methods for TCC quantification in clinical settings.
    • Standardized terminology for the terminal complement pathway is proposed to improve communication and research consistency.